Company* (Country; Symbol) University/ Non-Profit Type Of Agreement Product Area Details (Date) 3rd Millennium Inc.* Department of Defense Phase I SBIR contract To develop a bioinformatics system for the management and analysis of microarray data The work is supported by the U.S. Army Medical Research and Material Command; the system will advance the DOD's plan in infectious diseases (2/13) Acambis plc (UK; LSE:ACM) U.S. government Contract To manufacture and deliver 155M
Editor With cancer, heart disease, AIDS, hepatitis C and inflammatory devils such as rheumatoid arthritis tormenting the world populace, hardly anybody's losing sleep over insomnia. But most of those afflicted with the condition would pay dearly for a drug that would help them get shut-eye. About 85 million people in the U.S. suffer from sleep disorders, and the pharmaceutical information company IMS Health says the market in this country for prescription sleep products is almost $1 billion
By Randall Osborne | BioWorld Insight | Monday, March 25, 2002
Company* (Symbol) Product Description Indication Status (Date) CANCER Amgen Inc. (AMGN) Neulasta Pegfilgrastim; second generation of Neupogen Cancer FDA granted approval for Neulasta, which is injected once per chemotherapy cycle (2/1) Antigenics Inc. (AGEN) Oncophage Cancer vaccine; uses heat shock proteins to activate cellular immune responses Metastatic melanoma Company said the FDA granted fast-track designation for Oncophage (2/5) Corixa Corp. (CRXA
Company* (Symbol) Product Description Indication Status (Date) CANCER Micromet AG (Germany)* MT103 Bispecific antibody derivative B-cell lymphoma Company started a multicenter Phase I trial (2/13**) Oxford Bio- Medica plc (UK; LSE:OXB) MetXia and TroVax Cancer gene therapy products; MetXia delivers the gene CYP2B6 directly to solid tumors, where it generates an enzyme that converts the prodrug cyclophosphamide into its active, cytotoxic form; TroVax is based on a gene for
Company* (Symbol) Product Description Indication Status (Date) CANCER AltaRex Corp. (Canada; TSE:AXO) OvaRex Oregovomab; a fully foreign monoclonal antibody that targets CA125 Mestastatic ovarian cancer Company reported statistically significant and consistent results from its ongoing analysis of its OvaRex Phase IIb trial (2/7) Aphton Corp. (APHT) G17DT Anti-G17 immunogen Gastric cancer Phase II results showed no reported side effects when used in combination with
Editor If the genomics revolution moved biotechnology out of test tubes and into computers, companies with their eyes on reasonably timed profits have been trying to move it back. But the best way to do that, say the organizers of the Interoperable Informatics Infrastructure Consortium (I3C), is to make computers work better together. I3C's stated goal is a mouthful. The consortium wants "to develop common protocols and interoperable technologies (specifications and guidelines) for data
By Randall Osborne | BioWorld Insight | Monday, March 18, 2002
I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $241.6M Company Location Date Amt. (M) Details Agilix Corp. New Haven, Conn. 2/25 $7 Agilix raised $7M in its second round of financing, which began in December; investors were SAIC Venture Capital Corp., Temasek Capital, Burrill & Co., Hambrecht & Quist Capital Management, Stephens Group Inc., Wheatley MedTech Partners and VioVeda; Stephens Inc. acted as placement agent AM-Pharma BV Bilthoven, the Netherlands 2/26 ND AM-Pharma
Total: $2,779.81M Company (Symbol)# Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details (Date)@ Abgenix Inc. (ABGX) Private placement of convertible subordinated notes N/A $200 Abgenix raised $200M in the placement; the initial purchasers also have an overallotment option for up to an additional $50M in notes (2/27) Amgen Inc. (AMGN) Private placement of 30-year zero-coupon senior convertible notes Notes
I. COMMENCED TRADING IN FEBRUARY Company (Symbol)# Date Filed Date Comm. Shares/ Units (M) Price Shares Out (M) Lead, Other Underwriters Gross (M) Post-Offering Market Cap (M)@ INITIAL OFFERINGS ZymoGenetics Inc. (ZGEN)1 9/10 2/1 10S $12 45.6 Lehman Brothers (co-lead); Merrill Lynch (co-lead); Bear, Stearns Pacific Growth Equities $120 $547 Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ Market capitalization calculated is based on the
Editor The phrase "stem cells" can still bring a shudder to some investors, wisely shy about the riotous debate the field of research sparked last year between fervent camps of various persuasions some concerned more with religious and ethical matters than the advance of biotechnology. Not everyone understood what they were talking about, but this hardly mattered. When "stem cells" was spoken, "unborn babies" often got mentioned, even in cases where no aborted embryo was involved. The
By Randall Osborne | BioWorld Insight | Monday, March 11, 2002
I. COMPLETED MERGERS AND ACQUISITIONS Company Acquired (Country; Symbol) Acquired By Or Merged With (Country; Symbol) Date Announced Date Completed Value (M)*** Terms/Details Asys Hitech GmbH (Austria)* Harvard Biosciences Inc. (HBIO) 12/7 12/7 ND Harvard Bioscience acquired Asys, which should add about $1.5M to $2M in revenue for the company in 2002 Atlantic Stem Cells Inc.* Anthrogenesis Corp.* 12/6 12/6 ND Anthrogenesis acquired Atlantic Stem
Staff Writer Private biotech companies planning to go public played the waiting game in 2001. They waited for the right moment, when the window would fly up and investors would flock to their brokers. But just as that window started to inch open late last year, it immediately slammed shut again upon news of accounting scandals and clinical blowups. Only five biotech companies went public in the U.S. in 2001, and only one ZymoGenetics Inc. has gone public so far this year. A number of companies
By Karen Pihl-Carey | BioWorld Insight | Monday, March 4, 2002
I. MODIFIED AGREEMENTS Biotech Co.* (Country/ Symbol) Pharma Co. (Country) (M) Change from original agreement Disclosed Funding Terms/Details (Date) Albany Molecular Research Inc. (AMRI) Bristol-Myers Squibb Co. Agreement that replaces one between AMRI and DuPont Pharmaceuticals Co., which was acquired by Bristol-Myers ND The agreement is a new, three-year, multimillion-dollar agreement whereby Bristol-Myers will fund 30 fewer scientists than was called for in
Biotech Co.* (Country/Symbol) Pharma Co. (Country) Product Disclosed Funding (M) Terms/Details (Date) Actelion Ltd. (Switzerland; SWX:ATLN) Neopharm Ltd. (Israel) Tracleer ND Neopharm will be responsible for the registration, marketing and reimbursement of Tracleer in Israel (12/10) Actelion Ltd. (Switzerland; SWX:ATLN) Nova Factor Inc. (subsidiary of Accredo Health Inc.) and Gentiva Health Services Tracleer ND Nova Factor and Gentiva will distribute
Biotech Co.* (Country/ Symbol) Pharma Co. (Country) Type/Product Area Disclosed Funding (M) Terms/Details (Date) 3-Dimensional Pharmaceu- ticals Inc. (DDDP) GlaxoSmith- Kline plc (UK) Exclusive licensing agreement that gives 3DP worldwide development, marketing and distribution rights to a compound for a condition associated with chemotherapy $24.3 3DP will make an up-front payment of 500,000 shares, worth about $4.2M; it also will make milestone payments valued at about
Company* (Country; Symbol) University/ Non-Profit Type Of Agreement Product Area Details (Date) 3rd Millennium Inc.* Department of Defense Phase I SBIR contract To develop a bioinformatics system for the management and analysis of microarray data The work is supported by the U.S. Army Medical Research and Material Command; the system will advance the DOD's plan in infectious diseases (2/13) Acambis plc (UK; LSE:ACM) U.S. government Contract To manufacture and deliver 155M